RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) Short Interest Update

RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) saw a large increase in short interest in July. As of July 31st, there was short interest totaling 1,444 shares, an increase of 618.4% from the July 15th total of 201 shares. Based on an average daily volume of 3,592 shares, the short-interest ratio is presently 0.4 days. Approximately 0.0% of the company’s shares are sold short.

RCN Pareto Strategic Allocation ETF Price Performance

NYSEARCA PRTO remained flat at $28.18 during trading hours on Wednesday. The company had a trading volume of 8 shares. RCN Pareto Strategic Allocation ETF has a fifty-two week low of $24.68 and a fifty-two week high of $28.18. The firm has a market capitalization of $625.00 million, a PE ratio of -29.35 and a beta of 0.60.

Proteon Therapeutics was a biopharmaceutical company focused on developing treatments for patients with kidney and vascular diseases. The company’s research and development efforts centered on therapies designed to address severe and life-threatening conditions, particularly those related to renal disease and vascular access for hemodialysis patients.

One of Proteon Therapeutics’ best-known product candidates was vonapanitase, an investigational enzyme developed to improve vascular access outcomes in patients with end-stage renal disease who require hemodialysis.